AUG 2 5 2003 😽	•
	Application No.:
THE TO CO	Application No.: OMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES
NUCLEOTIDE	SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant' attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required to 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damage
and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other:
Applicant Must Provide:
An <u>initial</u> or substitute computer readable form (CRF) copy of the "Sequence Listing".
An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For questions regarding compliance to these requirements, please contact:
For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212 For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Example, Virginia 22313-1450

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
09/646,651	01/16/2001	Stefan Kissandi	206579	2260	
23460 7	7590 07/29/2003	(0, , ,)			
LEYDIG VOIT & MAYER, LTD TWO PRUDENTIAL PLAZA, SUITE 4900 AND 25 200			EXAM	EXAMINER	
180 NORTH S	NTIAL PLAZA, SUITE STETSON AVENUE	4900 AU6 13	SCHULTZ	SCHULTZ, JAMES	
CHICAGO, IL	. 60601-6780	FRAD PROPERTY.	ART UNIT	PAPER NUMBER	
			1635	17	
			DATE MAILED: 07/29/2003		
	''				

Please find below and/or attached an Office communication concerning this application or proceeding.

PEYONG, NOIT & MAYER MECENTED

RECEIVED

WAR MOIT & MAYER AUG 2 9 2003

AUG 0 4 2083 TECH CENTER 1600/2900





UNITED STATES DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO. CONTROL NO.

FIRST NAMED INVENTOR / PATENT IN REEXAMINATION ATTORNEY DOCKET NO.

PEADAS PALL & PHULES RECEIVED

EXAMINER

AUG 0 4 2003

ART UNIT PAPER

DATE MAILED:

TECH CENTER 95007 communication concerning this appl Please find below and/or attached an

proceeding.

Commissioner for Patents

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

The nucleotide sequences in applicants' sequence listing does not match the nucleotide sequences that are provided in the instant specification. Specifically, SEQ ID NO: 1 as provided on page 2 of the instant specification lists glutamines at positions 34 and 58, which contrasts with the SEQ ID NO: 1 of the sequence listing, which lists said positions as comprising tyrosines. Correction and/or amendment is required; in the case of amendment, applicants should clearly indicate by page and line number where written support exists in the specification for such amended material. Applicants are also informed that the above discrepancy is not intended as a complete description of all such discrepancies that may be contained in this application; applicants should carefully review the application for further errors.

APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.R.F. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner James Schultz, whose telephone number is (703) 308-9355. If the examiner cannot be reached, inquiries can be directed to Supervisory Patent Examiner John LeGuyader whose telephone number is (703) 308-0147. The fax number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

TECHNOLOGY CENTER 1600